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Abstract
AIM: To re-examine whether hepatic vein thrombosis 
(HVT) (classical Budd-Chiari syndrome) and hepatic 
vena cava-Budd Chiari syndrome (HVC-BCS) are the 
same disorder.
METHODS: A systematic review of observational 
studies conducted in adult subjects with primary BCS, 
hepatic vein outflow tract obstruction, membranous 
obstruction of the inferior vena cava (IVC), obliterative 
hepatocavopathy, or HVT during the period of January 
2000 until February 2015 was conducted using the follow-
ing databases: Cochrane Library, CINAHL, MEDLINE, 
PubMed and Scopus. 
RESULTS: Of 1299 articles identified, 26 were included 
in this study. Classical BCS is more common in women 
with a pure hepatic vein obstruction (49%-74%). HVC-
BCS is more common in men with the obstruction 
often located in both the inferior vena cava and hepatic 
veins (14%-84%). Classical BCS presents with acute 
abdominal pain, ascites, and hepatomegaly. HVC-BCS 
presents with chronic abdominal pain and abdominal 
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wall varices. Myeloproliferative neoplasms (MPN) are the 
most common etiology of classical BCS (16%-62%) with 
the JAK2V617-F mutation found in 26%-52%. In HVC-
BCS, MPN are found in 4%-5%, and the JAK2V617-F 
mutation in 2%-5%. Classical BCS responds well to 
medical management alone and 1st line management of 
HVC-BCS involves percutaneous recanalization, with few 
managed with medical management alone.
CONCLUSION: Systematic review of recent data 
suggests that classical BCS and HVC-BCS may be two 
clinically different disorders that involve the disruption 
of hepatic venous outflow. 
Key words: Budd-Chiari; Hepatic vein outflow tract 
obstruction; Membranous obstruction of the inferior 
vena cava; Obliterative hepatocavopathy; Hepatic vein 
thrombosis
© The Author(s) 2016. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: With improved diagnostic methods, the termi-
nology for Budd-Chiari syndrome (BCS) has expanded 
discordantly. This systematic review discusses recent 
population studies of BCS and proposes the delineation 
of two clinically unique syndromes.
Shin N, Kim YH, Xu H, Shi HB, Zhang QQ, Colon Pons JP, 
Kim D, Xu Y, Wu FY, Han S, Lee BB, Li LS. Redefining 
Budd­Chiari syndrome: A systematic review. World J Hepatol 
2016; 8(16): 691­702  Available from: URL: http://www.
wjgnet.com/1948­5182/full/v8/i16/691.htm  DOI: http://dx.doi.
org/10.4254/wjh.v8.i16.691
INTRODUCTION
Budd-Chiari syndrome (BCS) was originally described as 
a rare vascular disorder that encompasses an array of 
symptoms due to obstruction of hepatic blood outflow 
at the level of the hepatic veins or hepatic portion of the
inferior vena cava (IVC)[1]. The symptoms resulting 
from this type of occlusion of the hepatic outflow, “classi­
cal BCS”, were first described by Budd[2,3] in 1845 and 
later by Hans Chiari in 1899. With the advancement of 
diagnostic and therapeutic techniques, providers have
expanded upon these initial characterizations[4]. Histori-
cally, identifying the precise location of the obstruction 
was challenging, leading to the propagation of simplified 
descriptions. The precise location of the obstruction(s) 
is however clinically and prognostically significant. As 
Valla[5] proposed, the clinical manifestations of BCS 
(the selective group of symptoms that characterize 
the syndrome) can be explained by the location of the 
obstruction: Within the hepatic veins vs within the IVC 
at the level of the hepatic ostia. Over time, in order to 
incorporate novel and more detailed findings associated 
with BCS, the lexicon has evolved discordantly. The 
lexicon now includes a myriad of ambiguous terms or 
eponyms: Budd’s disease, Chiari’s disease, Chiari’s synd­
rome, Rokitansky’s disease, von Rokitansky disease, 
Hepatic vein outflow tract obstruction, membranous 
obstruction of the IVC, obliterative hepatocavopathy, 
Hepatic vena cava disease, Budd­Chiari syndrome with 
occlusion of hepatic vein, or hepatic vein thrombosis[6-8]. 
These eponyms have been used at some point during 
the course of further discovery; this disarray of terms, 
some of which are unclear and nonspecific, reflects not 
only the heterogeneous presentation of BCS, but also 
the possibility of distinct entities within this syndrome.
The currently accepted definition of primary BCS is 
hepatic outflow obstruction regardless of the cause or 
level of obstruction[6,9]. The obstruction can range from 
the small hepatic veins to the orifice of the IVC into the 
right atrium. Sinusoidal obstruction syndrome is excluded 
from this definition[6,9]. Secondary BCS is defined as a 
hepatic venous outflow obstruction due to compression 
or invasion by extravascular lesions, including benign or 
malignant diseases such as abscesses, hepatocellular 
carcinomas, and renal cell carcinomas, or secondary to 
cardiac or pericardial diseases[6,9]. 
In 1998, Okuda et al[4] proposed that primary hepatic 
venous thrombosis (classical BCS) and thrombosis 
of the IVC at the level of the IVC were two separate 
syndromes. Recent studies continue to suggest a clear 
division within the definition of “primary BCS” based on 
the location of the obstructive lesion[4,10]. Obstruction of 
the hepatic veins or “classical BCS” appears to be more 
common in Western patient populations and usually has 
a known etiology[11,12], acute onset of symptoms, and 
a greater severity of symptoms requiring a different 
therapeutic approach than obstruction of the IVC at 
the level of the hepatic veins[4,13,14]. In comparison with 
“classical BCS”, hepatic vena cava (HVC)­BCS appears 
to be more common in East Asian patient populations, 
and is more often idiopathic or due to membranous 
obstruction. HVC-BCS more commonly presents with a 
chronic onset of less severe symptoms, thus requiring 
a different therapeutic approach than “classical BCS”[15]. 
The location, size, and chronicity is clinically important 
as it dictates the patient’s symptoms and directs the 
therapeutic approach for patient management[10]. 
Precedence
Historically, hepatic sinusoidal obstruction syndrome 
(SOS) or veno-occlusive disease was included under the 
general term BCS[1,16­18]. SOS is specifically defined as 
obstruction of the sinusoids or hepatic veins resulting 
from sinusoidal wall injury. Several distinct clinical 
characteristics differentiate SOS from BCS and the 
two conditions are now considered separate entities 
as the distinct etiology and pathophysiology of SOS 
necessitates different management strategies. SOS is 
caused by pyrrolizidine alkaloid toxicity, whereas BCS 
is caused by multifactorial prothrombotic condition(s) 
or membranous obstruction of the IVC and/or HV[18]. 
Pyrrolizidine alkaloids include over 150 compounds that 
692 June 8, 2016|Volume 8|Issue 16|WJH|www.wjgnet.com
Shin N et al . Budd-Chiari syndrome review
occur naturally in several plant families[18]. Historically, 
they were ingested in indigenous herbal teas or 
inadvertently via crop contamination in developing 
countries. Currently, pyrrolizidine alkaloids are used 
as myeloablative regimens for patients preparing for 
hematopoietic stem cell transplantation. Thus, SOS 
almost exclusively affects hematopoietic stem cell 
transplant patients, while BCS can affect a wide range 
of patient populations[9]. Clinically, both SOS and BCS 
can present with abdominal pain, portal hypertension, 
jaundice, and non­cirrhotic ascites. Management of 
SOS is challenging and involves preventive measures 
(avoiding pyrrolizidine alkaloids in susceptible patients) 
and a few interventional therapeutic options (defibrotide, 
heparin, shunt procedures, etc.). In contrast, manage­
ment of BCS ranges from medical management (e.g., 
anticoagulation) to interventional procedures (angio-
plasty, stents, shunt procedures, etc.)[19].
Due to the low incidence of “BCS” in many countries, 
published data tended to include only small case series. 
Recently, there have been an increasing number of 
larger observational studies (both retrospective and 
prospective), particularly from Asia (China) and Europe. 
Advancing imaging technologies, such as computed 
tomography (CT) angiography, magnetic resonance (MR) 
angiography, Doppler ultrasound (US), and angiography 
have allowed for better identification and delineation of
this disease. This may signal the start of prospective, 
randomized, controlled therapeutic trials which can diffe­
rentiate classical BCS from HVC-BCS and their manage-
ment strategies. Other investigators have suggested 
various novel classification systems, including those 
that forego the eponym “Budd­Chiari” altogether[8-16]. 
However, given that both classical and HVC­BCS reflect 
an obstruction in hepatic venous outflow, we propose a 
clarification of the general BCS term into classical BCS 
and HVC-BCS. 
MATERIALS AND METHODS
A systematic literature search yielded 818 results in the 
PubMed database; 428 in the Scopus database; 18 in 
the CINAHL database; and 17 in the Cochrane database. 
All duplicates were removed. After 18 additional studies 
(from the references within included studies) were 
added, 1178 study abstracts were screened. Of these, 
591 were excluded because of the publication type and/
or subject (reviews, case reports including less than 20 
patients, non­human studies, or studies not on BCS (e.g., 
Chiari malformations, acute liver failure, etc.). The full 
text articles of the remaining 587 studies were acquired 
to determine eligibility. 
Inclusion criteria
Clinical trials and observational studies (prospective 
or retrospective) conducted in predominantly adult 
subjects with primary BCS were included in this study. 
All of the included studies needed to explicitly delineate 
diagnostic methods for BCS (namely standard imaging 
studies such as US, CT, MR imaging, or venography) 
and to explicitly describe inclusion and exclusion criteria 
to ensure the focus on primary BCS (vs secondary 
BCS). For multiple studies published from the same 
institution(s) within a close time frame, we reviewed 
years of subject recruitment, methodology specifics, and 
results. In addition, we also investigated if there were 
possible overlapping subjects and/or results. Only the 
most recent eligible studies were included in this review, 
unless distinctly specific and separate findings were 
previously reported[20,21]. 
Of the 587 studies, the following were excluded: 390 
were missing key clinical information (e.g., clear inclusion 
and exclusion criteria) or focused on a subpopulation 
within the BCS population (e.g., only BCS patients 
requiring liver transplantation, etc.); 71 studies were 
not limited to primary BCS; 86 studies were not mainly 
focused on BCS, but rather broader topics associated 
with BCS (e.g., causes of liver transplantation, etc.); 17 
studies were older versions of recently published subject 
populations with similar study aims. Twenty-six studies 
were included for analysis in this review (Figure 1).
RESULTS
Epidemiology
Many observational studies have recently been published 
on “BCS” (Table 1). For clarity and compromise, only 
the terms classical BCS and HVC-BCS will be used 
to differentiate between the two types of BCS in this 
review. After considering the location of the obstruction 
and clinical manifestations of the subjects, studies were 
grouped as majority-classical BCS or majority-HVC-BCS 
studies in Table 1. It has previously been suspected 
that classical BCS is more likely to present in women 
with a pure hepatic vein obstruction[9,13]. This review 
continues to support this observation as 13 of the 14 
included studies reported a higher incidence of classical 
BCS in women; 55%-76% of the reported population 
is female. In addition, recent studies continue to report 
pure obstruction in the majority of cases 49%-85%. 
Most studies reported pure hepatic vein obstruction in 
> 71% of patients (Table 1). Compared with classical 
BCS, HVC­BCS is more common in men (51%­66%) 
and more likely to present with an IVC obstruction with 
or without involvement of the HVs (69%­100%) (Table 
1).
Clinical manifestations in classical BCS vs HVC-BCS
Classical BCS typically presents with an acute onset of 
symptoms with most studies reporting the duration of 
symptoms < 6 mo (Table 2) with 60%­85% of patients 
having an acute presentation of symptoms; however, 
one study from Egypt designated 80% of their 94 patients 
as chronic, but the definitions of chronic vs acute were 
not explicitly delineated[22]. Classical BCS typically 
presents with abdominal pain (45%­86% of patients), 
ascites (76%­100%), and hepatomegaly (43%­83%) 
(Table 2). In comparison, HVC­BCS typically presents 
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BCS (Table 2)[13,23]. The severity of disease depends 
upon both the extent of disease (the number of occluded 
vessels, complete or incomplete occlusion), the presence 
of associated symptoms (refractory ascites, portal vein 
thrombosis, etc.), and the chronicity of symptoms. 
Patients with the chronic variation of disease generally 
have several milder episodes of vague symptoms (abdo-
minal pain or leg swelling), providing sufficient time for 
with chronic onset of symptoms (75%­86% of patients), 
with an average duration of symptoms prior to diagnosis 
ranging from 44-96 mo. Nine to seventy percent of 
patients (most studies reporting < 29%) with HVC-BCS 
present with abdominal pain, 32%­90% with ascites, 
and 28%­95% with hepatomegaly. Splenomegaly, 
abdominal wall varices, lower extremity varices, and 
discoloration are more commonly associated with HVC-
1281 studies (818 PubMed, 428 
Scopus1, 18 CINAHL1, 17 Cochrane1)
587 full-text articles 
assessed for eligibility
26 studied included in analysis
1178 screened 591 excluded
390 missing key clinical/study design information2
86 not focused on BCS3
71 not primary BCS
17 previously published subject publication
After duplicates removed: 1178
18 records from 
references within studies
Figure 1  Flow diagram of studies selection. 1Searches conducted with MEDLINE results removed; 2Studies missing key clinical information including clear 
inclusion and exclusion criteria, clear diagnostic parameters, etc., and studies that investigated subpopulations (e.g., BCS patients requiring liver transplantation, BCS 
patients without MPN, etc.); 3Studies focused on other categories (e.g., causes of liver failure). BCS: Budd-Chiari syndrome; MPN: Myeloproliferative neoplasms.
Table 1  Epidemiology of classical Budd-Chiari syndrome and hepatic vena cava-Budd Chiari syndrome
Ref. Country Publication Recruitment n Age Gender Location of obstruction (%)
date years (median) M (%) F (%) HV IVC Both
Janssen et al[27] The Netherlands 2000 1984-1997     43 40   16 (37)   27 (63)
Perelló et al[40] Spain 2002 1990-2000     21  361     5 (24)   16 (76) 17 (81) 0 (0)     4 (19)
Colaizzo et al[30] Italy 2008 1997-2006     32 35     9 (28)   23 (72)
Darwish Murad et al[24] Europe 2009 2003-2005   163 38   70 (43)   93 (57) 80 (49) 4 (2)   79 (48)
Xavier et al[31] Brazil 2010 2000-2008     31 33   11 (35)   20 (65)
Sakr et al[22] Egypt 2011 2009-2011     94     28.81   36 (38)   58 (62) 70 (74) 3 (3)   16 (17)
Deepak et al[29] India 2011 2006-2009     20    36.6   14 (70)     6 (30) 17 (85) 1 (5)     2 (10)
Rautou et al[37] France 2011 1995-2005     94  381   34 (36)   60 (64) 73 (78)   13 (14)
Raszeja-Wyszomirska et al[45] Poland 2012 2004-2011     20 38     9 (45)   11 (55)
Westbrook et al[32] United Kingdom 2012 1985-2008     66 36   27 (41)   39 (59)
D’Amico et al[34] Italy 2013 2005-2011     31 46   14 (45)   17 (55)
Harmanci et al[42] Turkey 2013 1989-2011     62     42.81   26 (42)   36 (58) 35 (56)   8 (14)   19 (30)
Nozari et al[47] Iran 2013 1989-2012     55 291   22 (40)   33 (60)
Pavri et al[38] United States 2014 2008-2013     47    42.4   16 (34)   31 (66)
Faraoun et al[25] Algeria 2015 2008-2012   176  331   75 (43) 101 (57)   125 (71) 0 (0)   51 (29)
De et al[23] India 2001 1992-1998     40     35.21   26 (65)   14 (35) N/A 23 (72)     9 (28)
Xu et al[41] China 2004 1983-2003 1360     33.21 833 (61) 527 (39) 2 (0) 1358 (100)2
Ebrahimi et al[46] Iran 2011 2002-2008     21  421   11 (52)   10 (48)   6 (29) 12 (57)     3 (14)
Park et al[51] South Korea 2012 1988-2008     67 47   34 (51)   33 (49) 5 (7) 56 (84)   6 (9)
Qi et al[35] China 2013 1999-2011   169     38.31   66 (52)   61 (48) 53 (31) 20 (12)   96 (57)
Cheng et al[13] China 2013 2010-2011   145 46 90 (6)   55 (38) 45 (31) 8 (6)   92 (63)
Qi et al[36] China 2014 2012-2012     25     35.71   14 (56)   11 (44)   4 (16) 0 (0)   21 (84)
Zhou et al[26] China 2014 2006-2010   338     41.71 209 (62) 129 (38) 45 (13) 8 (2) 285 (84)
Gao et al[49] China 2015 2008-2012
R     98  363   62 (63)   36 (37) 31 (32) 26 (27)   41 (42)
NR   373  453 193 (52) 180 (48) 82 (22)   169 (45) 122 (33)
1Mean values; 2No differentiation between IVC alone vs both IVC and hepatic vein; 3Provided median ages for the two groups separately. R: Recurrence of 
disease, NR: Non-recurrence of the disease; HV: Hepatic vein; IVC: Inferior vena cava; M: Male; F: Female; N/A: Not available.
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MPN were only found in 4%­5% of patients (PV in 2% 
and ET in 1%-2%) and the JAK2V617-F mutation in 
only 0%­5% of patients diagnosed with primary HVC­
BCS (Table 4)[13,35,36]. 
Hereditary prothrombotic conditions such as factor 
Ⅴ Leiden mutation (FVL), prothrombin (PT) 20210A 
mutation, protein C deficiency (PCD), protein S defi­
ciency (PSD), antithrombin deficiency (ATD), plasmi­
nogen activator inhibitor [PAI­1 (4G­4G)], and the 
5,10­methlenetetrahydrofolate reductase enzyme 
mutation (MTHFRC677T) often also play a significant 
role in the development of classical BCS. Following 
MPNs, the FVL mutation is the second most common 
cause of classical BCS and was found in 2%­53% of 
patients. Thrombophilic conditions also may contribute 
to the development of classical BCS. Mutations in PT 
were found in 2%-8% of patients with classical BCS vs 
0% of patients with HVC­BCS. PCD, PSD, and ATD were 
found in 3%­26%, 1%­9% and 3%­15% of patients 
with classical BCS, respectively, vs 0% of patients with 
HVC­BCS (Table 4). Interestingly, this pattern is not 
apparent with MTHFRC677T mutations; these mutations 
were found in 26%-52% of patients with classical 
BCS and 71%-72% of patients with HVC-BCS. Less 
common but established prothrombotic or associated 
conditions further include antiphospholipid antibodies 
(classical BCS: 3%­29% vs HVC­BCS: 0%­17%), 
hyperhomocysteinemia (10%­18% vs 21%­50%), and 
paroxysmal nocturnal hemoglobinuria (0%­19% vs 
0%­4%). Several systemic conditions (classical BCS: 
5%-24% vs HVC-BCS: 1%-19%) including connective 
tissue disorders such as systemic lupus erythematosus 
(5%-12% vs 1%) are generally associated more 
frequently with classical BCS. Hormonal factors such 
as oral contraceptives, pregnancy, or puerperium can 
also increase the risk of thrombosis as can local insults 
such as recent surgery. Of these numerous differences 
between classical BCS and HVC­BCS, one consistent 
difference is the greater influence of hormonal changes 
(be it oral contraceptive use or pregnancy) in classical 
BCS patients (4%-52% of the female population) (Table 
4)[29,37­39].
Membranous obstruction of the IVC (and/or HV) 
is consistently listed as the etiology of a significant 
number of HVC-BCS patients (52%-61%). In classical 
BCS patients, membranous obstruction is rare (1%) 
or rarely explicitly delineated, except in one study 
of 23 consecutive patients diagnosed with BCS in 
Germany where 5 patients (22%) were found to have 
a membranous obstruction of the IVC[24]. Furthermore, 
despite comprehensive work­up, an etiologic factor is 
often not identified in HVC­BCS patients (19%­29% vs 
classical BCS: 5%­30%) (Table 4). 
Data from recent studies continues to support the 
possibility of two different types of BCS with separate 
etiologies: Classical BCS, where thrombophilic risk 
factors and often multiple concomitant factors are 
common vs HVC­BCS, where thrombophilic risk factors 
are uncommon, but membranous obstruction and 
idiopathic hepatic venous outflow obstruction are more 
common.
Management and outcomes
Treatment and prognosis of BCS depends on a few key 
factors: Acuity of symptoms, location and extent of 
the obstruction, and etiology[24]. In 2013, Seijo et al[11] 
outlined a step-wise management approach for BCS 
patients from the analysis of the extended follow-up 
data of 157 patients from 9 European countries. This 
management approach starts with medical management 
alone (e.g., salt­restriction, anticoagulation, diuretics), 
including concomitant management of any underlying 
etiological processes. Diagnostic work­up for classical 
BCS patients generally includes hematologic work­up 
for MPN, JAK2V617F mutation screening for MPN[29­31,33], 
testing for FVL mutation[28], and the aforementioned 
thrombophilic risk factors. In addition, some studies 
recommend continued monitoring of JAK2-mutation-
positive­patients for occult MPNs[5,9,33]. In general, the 
medical management of classical BCS patients involves 
anticoagulation and ascites management with diuretics. 





Figure 2  Classical Budd-Chiari syndrome - Occlusions are within the 
hepatic veins themselves and usually thrombi. RHV: Right hepatic vein; 





Figure 3  Hepatic vena cava-Budd Chiari syndrome - Occlusions are thin 
or thick (membranous or segmental) and within the inferior vena cava 
and occlusion can extend into the hepatic veins and generally involve the 
ostia to the inferior vena cava. RHV: Right hepatic vein; MHV: Middle hepatic 
vein; LHV: Left hepatic vein; IVC: Inferior vena cava.
Shin N et al . Budd-Chiari syndrome review


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Shin N et al . Budd-Chiari syndrome review









































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Shin N et al . Budd-Chiari syndrome review











































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































   






























































































































   
75
%





















































































































































































































































































































































































































































































































































































































































































































































Shin N et al . Budd-Chiari syndrome review
700 June 8, 2016|Volume 8|Issue 16|WJH|www.wjgnet.com
with the actual benefit the patient may gain should be 
BCS­type specific.
Treatment and prognosis of BCS depends on a 
few key factors: Acuity and severity of the symptoms, 
location and the extent of the obstruction, and etiology 
of the obstruction[24]. While anticoagulation (initially 
with heparin and chronically with warfarin) is the initial 
treatment of choice for both classical BCS and HVC-
BCS patients[45], the expected response and course of 
therapy differs dramatically. Classical BCS patients often 
present with acute thrombosis of the hepatic veins. 
This rapid blockage of hepatic venous outflow precludes 
the ability to adapt via the development of collateral 
circulation. It is not surprising then that acute fulminant 
liver failure (with its sequelae) is more common among 
classical BCS patients, thus requiring shunt operations 
and liver transplantations more frequently than in 
HVC-BCS patients[13]. In contrast, HVC­BCS patients 
generally present with chronic symptoms that may 
lead to the transformation of an old thrombus into a 
fibrous, membranous obstruction[7,25]. Depending on 
the thickness and the extent of the obstruction, early 
interventional therapy (most commonly PTA with or 
without stent deployment), is very effective and thus 
more commonly utilized among HVC-BCS patients[13,46]. 
The thrombotic nature of obstruction observed in 
classical BCS may explain why these obstructions are 
more susceptible and responsive to medical manage-
ment (namely anticoagulation) alone. As noted in 
two long-term follow up studies by Perelló et al[40] and 
Darwish Murad et al[24] (with median follow-ups of 58 
and 17 mo respectively) of predominantly classical BCS 
patients, 33%­44% of patients that were maintained on 
medical management alone had good outcomes: 100% 
and 44% (at 12 mo), respectively. In both studies, 
very few classical BCS patients (5%-9%) required 
percutaneous recanalization. In HVC­BCS patients, 
the role of anticoagulation is often adjunctive and 
temporary; the use of warfarin before angioplasty can 
improve outcomes in patients with IVC obstruction[47]. 
Few HVC-BCS patients are managed with medical 
management alone because of previously reported poor 
outcomes[38]. In terms of the pathophysiology, Simonetto 
et al[48] recently used a murine model to demonstrate 
that hepatic venous outflow obstruction as seen in 
congestive heart failure or veno-occlusive disease led 
to liver fibrosis not via an inflammatory pathway, but 
via sinusoidal thrombosis and mechanical strain, while 
also showing that anticoagulation may have a beneficial 
effect in decreasing fibrosis. This aids our understanding 
of the mechanism by which BCS and HVC-BCS can 
result in fibrosis, and emphasizes the need for relief of 
obstruction for proper management. Given the different 
presentations and treatment courses of the two entities, 
it would be relevant to further study the pathophysiology 
of these conditions to better optimize management.
Factors that contribute poor prognosis in classical 
BCS include: Increasing age, cirrhosis at the time of 
diagnosis, chronic kidney disease, and portal vein 
thrombosis[25,38]. The Child­Pugh and MELD scores also 
play an unclear role in terms of practical management, 
while asymptomatic patients generally have better 
prognoses[45,49]. For HVC­BCS patients, factors that 
contribute to poor prognosis include the development of 
cirrhosis and HCC. Recent studies have suggested that 
the risk of developing HCC in HVC­BCS patients (unlike 
classical BCS patients) is directly attributable to the 
disease vs Hepatitis B or C infections[7]. Furthermore, 
the incidence of developing HCC in HVC-BCS patients 
is similar to those of cirrhotic patients[50,51]. These 
findings suggest that HVC­BCS patients, unlike classic 
BCS patients, should be routinely monitored for the 
development of HCC. Specific interventions to address 
and reduce the high pressure gradient in BCS patients 
may reduce the risk of HCC development.
In conclusion, clarification in the terminology descri­
bing hepatic venous outflow obstruction would enable 
both clinicians and investigators to identify patients with 
comparable signs and symptoms, thus enabling the 
execution of sound (randomized and controlled) and 
separate research studies on pathogenesis, therapy, and 
prognosis of what seems to be two different etiologies 
of Budd­Chiari syndrome. As summarized in this review, 
recent studies continue to support that classical and 
HVC­BCS have distinct demographics, characteristics, 
etiologies, therapeutic strategies, and prognoses. To 
address gaps in knowledge within classical BCS and 
HVC­BCS patients, these differences should be acknow­
ledged and future research should be performed on 
these two conditions separately.
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